Oral N-acetylcysteine in prevention of contrast induced nephropathy following coronary angiogram

International Medical Journal

Volumn 15, Issue 5, 2008, Pages 353-361

  Izani Wan Mohamed, Wan Mohd ^a   Darus, Zainal ^a   Yusof, Zurkurnai ^a  

^a HOSPITAL UNIVERSITI SAINS MALAYSIA   (Malaysia)

Author keywords

Contrast induced nephropathy; Coronary angiography; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IOHEXOL; PLACEBO; SODIUM CHLORIDE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTRAST INDUCED NEPHROPATHY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYDRATION; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR;

EID: 58549089575     PISSN: 13412051     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ahizaid A, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast induced acute renal failure after coronary angioplasty in patients with pre-existing renal insufficiency. Am J Cardiol 1999; 83: 260-3.
2. Andrews NP, Prasad A, Quyymi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol 2001; 37: 117-23.
3. Bailey SR. Past and present attempts to prevent radiocontrast nephropathy. Rev Cardiovasc Med 2001; 2(Suppl 1): S14-8.
4. Baker CSR, Wragg A, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPIDD study. J Am Col Cardiol 2003; 41: 2114-8.
5. Berns AS. Nephrotoxicity of contrast media. Kidney Int 1989; 36: 730-40.
6. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, et al. Acetylcysteine and contrast agent-associated nephrotoxicity J Am Coll Cardiol 2002; 40(2): 298-303.
7. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86(6 Pt 1): 649-52.
8. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89(3): 356-8.
9. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62(6): 2202.
10. Eisenberg RL, Bank WO, Hedgcock MW. Renal failure after major angiography. Am J Med 1980; 68: 43-6.
11. Goldenberg I, Micheal S, Matetzky S, Jonas M, Adam M, Pres H, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. European Society of Cardiology 2004; 25: 212-218
12. Gomes VO, Poli de Figueredo CE, et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 2005; 91:774-778.
13. Heyman SN, Rosen S. Dye-induced nephropathy. Semin Nephrol 2003; 23(5): 477-85.
14. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital acquired renal insufficiency: a prospective study. Am J Med 1983;74: 243-8.
15. Iakovou I, Dangas G, Lansky AJ, et al. Incidence, predictors, and economic impact of contrast induced nephropathy; results in 8,628 patients treated with percutaneous coronary coronary interventions. 51st Annual Sessions of the American College of Cardiology 2002; 4: 372-9.
16. Jones AL, Haynes W, MacGilchris.t et al. N-acetylcysteine is a potent peripheral vasodilator. Gut 1994; 35(Suppl 5): S10.
17. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003; 289(5): 553-8.
18. Kini AS, Mitre CA, Kamran M, et al. Changing trends in incidence and predictors of radiographic contrast nephopathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002; 89: 999-1002.
19. Kshirsagar AV, Poole C, Mottl A, Shoham D, Franceschini N. Tudor G, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004; 15(3): 761-9.
20. Levy EM, Viscloi CM, Howitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-94.
21. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, et al. N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty. NEJM 2006; 354: 2773-2782.
22. Mason RA, Arbeit LA, Giron F. Renal dysfunction after arteriography. JAMA 1985; 253: 1001-4.
23. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients under-going coronary angioplasty. Arch Intern Med 2002; 162(3): 329-36.
24. Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high risk patient and the implications of exacerbating renal function. Rev Cardiovascular Med 2003.
25. Oldenmyer JB, Biddle WP, et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Jeart J 2003; 146: e23.
26. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989; 320(3): 143-9.
27. Parfrey PS, Griffiths SM, Barren BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989; 320(3); 143-9.
28. Rich MW, Crecelius CA. Incidence, risk factors and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age and older. A prospective study. Arch Int Medicine 1990; 150; 1237-42.
29. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105(19): 2259-64.
30. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47(1): 254-61.
31. Shyu KJ, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002; 40: 1383-8.
32. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int 1998; 53(1): 230-42.
33. Soma VR, Cavusoglu E, Vidhun R, Frishman WH. Contrast associated nephropathy. Heart Dec 2002.
34. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343(3): 180-4.
35. Vliestre RE, Nunn CM, Naverete J, Browne KF. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency, Am Heart J 1996; 32: 1049-50.
36. Weinrauch LA, Healy RW, Leland OS Jr, Goldstein HH, Kassissieh SD, Libertino JA, et al. Coronary angiography and acute renal failure in diabetic azotemic nephropathy. Ann Intern Med 1977; 86(1): 56-9.
37. Zhang H, Spapen H, et al. Effects of N-acetylcyteine on regional blood flow during endotoxic shock. Eur Surg Res 1995; 27: 292-300.